Bikle Daniel D
Medicine and Dermatology, University of California and Veterans Affairs Medical Center, San Francisco, California, USA.
Curr Opin Rheumatol. 2007 Jul;19(4):383-8. doi: 10.1097/BOR.0b013e32818e9d58.
This review focuses on recent developments in a number of areas to bring the reader up to the current state of knowledge in this field.
A number of studies have revealed new insights into the regulation of the vitamin D receptor and new targets for its action. The mechanism by which a number of drugs can reduce circulating 25OHD has been clarified. New drug targets including increased bone by inhibition of osteoclasts, improvement in diabetes mellitus, and stimulation of innate immunity to combat infections such as tuberculosis have been found.
The wide distribution of the vitamin D receptor provides a number of clinical targets for vitamin D and its analogs. The wide distribution of CYP27B1, the enzyme required to convert circulating 25OHD to 1,25(OH)2D enables a number of cells to make their own 1,25(OH)2D3 if circulating 25OHD levels are maintained. These newer studies emphasize that vitamin D is not just for bones, and maintaining adequate levels is important for many tissues.
本综述聚焦于多个领域的近期进展，以使读者了解该领域的当前知识状态。
多项研究揭示了维生素D受体调控方面的新见解及其作用的新靶点。多种药物降低循环25羟维生素D水平的机制已得到阐明。已发现新的药物靶点，包括通过抑制破骨细胞增加骨量、改善糖尿病以及刺激先天免疫以对抗结核病等感染。
维生素D受体的广泛分布为维生素D及其类似物提供了多个临床靶点。CYP27B1（将循环25羟维生素D转化为1,25(OH)2D所需的酶）的广泛分布使得如果循环25羟维生素D水平得以维持，许多细胞能够自行合成1,25(OH)2D3。这些最新研究强调维生素D不仅对骨骼有益，维持足够水平对许多组织也很重要。
Zotero 插件